학술논문

The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers
Document Type
Article
Source
In: Molecular Cancer Therapeutics. (Molecular Cancer Therapeutics, 1 March 2015, 14(3):692-703)
Subject
Language
English
ISSN
15388514
15357163